Absorption and Distribution of Glucosamine and Chondroitin
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The purpose of this study is to examine the way the dietary supplements glucosamine and chondroitin are absorbed and distributed throughout the body.
| Condition | Intervention |
|---|---|
|
Osteoarthritis |
Drug: Glucosamine Drug: Chondroitin |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Pharmacokinetics Study Intervention Model: Parallel Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Pharmacokinetic Study of Glucosamine and Chondroitin |
| Estimated Enrollment: | 70 |
| Study Start Date: | April 2004 |
| Estimated Study Completion Date: | January 2006 |
Osteoarthritis is the most common musculoskeletal disease in the world. While predisposing conditions have been identified, the actual cause of osteoarthritis remains unknown. Traditional treatments, most often anti-inflammatory drugs and pain relievers, produce variable results and may cause significant toxicity. The use of complementary and alternative therapies in the treatment of osteoarthritis has become more common, and particular interest has focused on glucosamine and chondroitin treatments. This study will examine the pharmacokinetics of glucosamine and chondroitin.
This study consists of two phases. In Phase I, participants will have two study visits, during which multiple blood samples will be taken to determine levels of glucosamine and chondroitin found naturally in the body. During Phase II, participants will be randomly assigned to receive glucosamine, chondroitin, or a combination of the two for 3 months. Blood samples will be taken at each of the three Phase II study visits to examine the pharmacokinetics of glucosamaine and chondroitin.
Eligibility| Ages Eligible for Study: | 21 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
- Able to walk
Exclusion Criteria:
- Allergy to glucosamine, chondroitin, or shellfish
- Liver or kidney disease
- Diabetes mellitus
- Concurrent use of other complementary or alternative therapies
Contacts and Locations| United States, Utah | |
| University of Utah Health Sciences Center | |
| Salt Lake City, Utah, United States, 84132 | |
| Principal Investigator: | Christopher G. Jackson, MD | University of Utah |
More Information
No publications provided
| ClinicalTrials.gov Identifier: | NCT00086229 History of Changes |
| Other Study ID Numbers: | R21 AT001938-01 |
| Study First Received: | June 28, 2004 |
| Last Updated: | August 16, 2006 |
| Health Authority: | United States: Federal Government |
Keywords provided by National Center for Complementary and Alternative Medicine (NCCAM):
|
Complementary Therapies |
Additional relevant MeSH terms:
|
Osteoarthritis Arthritis Joint Diseases Musculoskeletal Diseases Rheumatic Diseases |
ClinicalTrials.gov processed this record on May 19, 2013